Home › Research › Biomarkers
Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study
Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, Mattsson-Carlgren N, Veverova K, Fowler CJ, Boonkamp L, Houtkamp IM, Koel-Simmerlink M, et al.. Alzheimer's & Dementia, 2025-06
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Plasma phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), and amyloid beta ratio (Aβ42/40) may have diagnostic and prognostic value in Alzheimer's disease (AD). Here we assess which markers can best identify AD from controls and other non-AD dementias in a large international multi-center study. Methods Plasma samples (n = 1298) were collected from six international centers. Aβ40, Aβ42, GFAP, NfL, and p-tau181 were measured using single molecule array. In each group, AD diagnosis/co-pathology was defined according to cerebrospinal fluid biomarkers or amyloid positron emission tomography. Validations were performed in three separate cohorts via single and dual cut-off models. Results p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies. However, this discriminative power could not be reproduced by applying pre-defined cut-offs. Discussion p-tau181 was the best single plasma marker for detecting AD at any stage. Specific cut-offs are needed to maximize diagnostic performances. Highlights Phosphorylated tau (p-tau)181 provided a clear differentiation between controls and Alzheimer's disease (AD) participants, with evidence of increased levels in the preclinical stage of AD. Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB. Given the low prevalence of amyloid co-pathology in frontotemporal dementia (FTD), p-tau181 and its ratio with amyloid beta 42 are strong biomarkers to differentiate FTD from AD.
What this study adds
Evidence grade: Moderate
This is a cross-sectional study of 1,298 participants. The authors conclude that specific cut-offs are needed to maximize diagnostic performance, so this is about diagnosis rather than treatment, cure, or prevention. Its stated limit: Kit-lot differences between cohorts could not be bridged, so validation AUCs may be underestimated; subgroup sizes for MCI due to FTD and DLB were small; validation groups were limited in size, and a uniform international cut-off may not be achievable with these biomarkers.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Doecke, J. D., Bellomo, G., Vermunt, L., Alcolea, D., Halbgebauer, S., In 't Veld, S., et al. (2025). Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimer's & Dementia. https://doi.org/10.1002/alz.14573
Vancouver
Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, et al. Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimer's & Dementia. 2025. doi:10.1002/alz.14573. PMID: 40551285.
BibTeX
@article{doecke2025-40551285,
author = {Doecke, J. D. and Bellomo, G. and Vermunt, L. and Alcolea, D. and Halbgebauer, S. and In 't Veld, S. and Mattsson-Carlgren, N. and Veverova, K. and Fowler, C. J. and Boonkamp, L. and Houtkamp, I. M. and Koel-Simmerlink, M. and others},
title = {{Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study}},
journal = {Alzheimer's \& Dementia},
year = {2025},
doi = {10.1002/alz.14573},
pmid = {40551285},
url = {https://doi.org/10.1002/alz.14573}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results p-tau181 showed the best area under the curve value to separate AD from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies.
- Plasma biomarkers demonstrated that when amyloid co-pathology is removed from dementia with Lewy bodies (DLB), only glial fibrillary acidic protein and neurofilament light chain remain to predict DLB.
Why it matters
In this cross-sectional international multi-center study of 1298 plasma samples, p-tau181 showed the best area under the curve for separating Alzheimer's disease from frontotemporal dementia, controls, and Aβ- dementia with Lewy bodies, but this discriminative power could not be reproduced using pre-defined cut-offs. The authors conclude that specific cut-offs are needed to maximize diagnostic performance, so this is about diagnosis rather than treatment, cure, or prevention.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Study designcross-sectional
- Participants1,298
- Evidence strengthModerate
Limitations
Kit-lot differences between cohorts could not be bridged, so validation AUCs may be underestimated; subgroup sizes for MCI due to FTD and DLB were small; validation groups were limited in size, and a uniform international cut-off may not be achievable with these biomarkers.
How this study scored 52/100
Published in a leading specialty journal, and it is a snapshot of people at one point in time. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, institution's track record and free to read, so those were left out: it earned 47 of the 91 points we could judge it on, which is 52 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Alzheimer's & Dementia) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 4 / 12 | A snapshot of people at one point in time |
| Strength of evidence | 3 / 5 | Rated “moderate” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 3 / 4 | 1,298 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 3 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.0 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 2 / 6 | Cited 1.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 3 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 4 / 4 | Last-listed author Charlotte Elisabeth Teunissen: h-index 116 (OpenAlex, whole career) |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40551285) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 47 / 91 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 47 of the 91 points we could judge it on is 52 out of 100. |
| Total | 52 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “cerebrospinal”
820 studies in the library carry the topic tag “cerebrospinal”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 820 tagged studies.